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Abstract  
Purpose: The six-minute walk test (6MWT) is one of an useful measure to evaluate exercise capacity 
with simple method. The kinetics of oxygen uptake (V
㸬
O2) throughout constant load exercise on 
cardiopulmonary exercise testing (CPX) are composed of three phases and the V
㸬
O2 kinetics are 
delayed in patients with heart failure (HF). This study aimed to investigate the kinetics of the 
cardiorespiratory response during and after the 6MWT according to exercise capacity. 
Methods: Forty-nine patients with HF performed CPX and the 6MWT. They were divided into two 
groups by 6MWT distance: 34 patients walked ≥ 300 m (HF-M), and 15 patients walked < 300 m 
(HF-L). V
㸬
O2, minute ventilation (V
㸬
E), breathing frequency, tidal volume, and heart rate both during 
and after the 6MWT were recorded. The time courses of each parameter were compared between the 
two groups. CPX was used to assess functional capacity and physiological responses. 
Results: In the HF-M group, V
㸬
O2 and V
㸬
E stabilized from 3 min during the 6MWT and recovered for 
3 min, respectively, after the 6MWT ended. In the HF-L group, V
㸬
O2 and V
㸬
E stabilized from 4 min, 
respectively, during the 6MWT and did not recover within 3 min after the 6MWT ended. On CPX in 
the HF-M group, V
㸬
O2 peak, and anaerobic threshold were significantly higher, while the relationship 
between minute ventilation and carbon dioxide production was lower compared with the HF-L group. 
Conclusion: In lower exercise capacity patients with HF had slower V
㸬
O2 and V
㸬
E kinetics during and 
after the 6MWT. 
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INTRODUCTION 1 
 Heart failure (HF) is a common disease, and people living with HF have increased worldwide. 2 
In particular, the number of elderly patients with HF is predicted to gradually increase as the 3 
population ages (Inamdar, and Inamdar, 2016; Metra et al., 2007; Ponikowski et al., 2016; Writing 4 
Committee Members et al., 2013). The main symptoms of HF are dyspnea and fatigue, which may 5 
lead to low exercise capacity (Inamdar, and Inamdar, 2016; Metra et al., 2007; Ponikowski et al., 6 
2016). Exercise capacity has commonly been evaluated by cardiopulmonary exercise testing (CPX), 7 
and one of the best indicators during CPX is oxygen uptake (V
㸬
O2) (Guazzi et al., 2016; Inamdar, and 8 
Inamdar, 2016; Metra et al., 2007; Piepoli et al., 2011; Writing Committee Members et al., 2013). It 9 
has been well established that the kinetics of V
㸬
O2 during constant load exercise are composed of three 10 
phases. Phase I takes place within the first breath and continues for 15-20 sec; phase II is more 11 
gradual and increases exponentially until the steady-state is reached, lasting two to three minutes; and 12 
phase III is a steady state or slow drift (Wasserman, Hansen, Sue, and Whipp, 1987; Brunner-La et al., 13 
1999). In patients with cardiovascular disease including HF, these V
㸬
O2 kinetics during and after CPX 14 
are delayed (Fleg et al., 2015; Koike et al., 1995; Sietsema et al., 1994). In the clinical field, despite 15 
several previous reports using CPX, cycle and treadmill CPX are unsuitable for some HF patients, 16 
especially elderly patients, who have co-morbidities (such as frailty and patients with arthralgia) (Fleg 17 
et al., 2015; Piepoli et al., 2011; Ponikowski et al., 2016; Vigorito et al., 2017). These prior studies 18 
have mainly involved chronic patients and outpatients with HF (Fleg et al., 2015; Koike et al., 1995; 19 
Sietsema et al., 1994). Nonetheless, health professions also have to prescribe exercise training for 20 
acute and hospitalized HF patients (Mebazaa et al., 2015; Piepoli et al., 2011). Discharge planning 21 
that includes exercise training should begin as soon as the patient’s condition is stable (Papathanasiou, 22 
Tsamis, Georgiadou, and Adamopoulos, 2008; Piepoli et al., 2011; Ponikowski et al., 2016). 23 
Furthermore, exercise training guidelines for patients with HF recommend aerobic exercise (Fleg et 24 
al., 2015; Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008). In particular, walking can be 25 
simple and inexpensive without special equipment (Fleg et al., 2015), and it can be continued in every 26 
hospitalization phase and in the after discharge phase of HF.  27 
Several guidelines suggest that the six-minute walk test (6MWT) is useful for measuring 28 
㸰 
 
exercise capacity in patients with HF (Kervio et al., 2004; Lipkin, Scriven, Crake, and Poole-Wilson, 1 
1986; Metra et al., 2007; Writing Committee Members et al., 2013). Additionally, the distance walked 2 
during 6MWT (the 6-minute walk distance: 6MWD) is an important prognostic marker, and 6MWD < 3 
300 m is an objective definition of advanced HF (Metra et al., 2007; Writing Committee Members et 4 
al., 2013). HF has been confirmed as a disease of the elderly population (Inamdar, and Inamdar, 2016; 5 
Metra et al., 2007; Ponikowski et al., 2016; Writing Committee Members et al., 2013), and it is 6 
necessary to provide a simple measure of those that puts little load on elderly and infirm patients. 7 
Therefore, 6MWT may be a simple and easy measure without a special measuring device. One study 8 
identified that the V
㸬
O2 steady state during 6MWT is delayed in HF patients compared with healthy 9 
participants (Kervio et al., 2004). However, no previous study has demonstrated the kinetics of V
㸬
O2 10 
and ventilatory response differences during the 6MWT and during the recovery time course after 11 
6MWT according to exercise capacity in patients with HF. 12 
Therefore, in the present study, the aim was to investigate: 1) the difference in the 13 
cardiorespiratory response during and after the 6MWT between groups divided according to exercise 14 
capacity; and 2) the differences in the patterns of breathing during the 6MWT. 15 
 16 
METHODS 17 
Participants 18 
Patients who were hospitalized for HF at our institution from January 2015 to April 2017 19 
were prospectively analyzed. A flow chart of patients included in this study is shown in Figure 1. Of 20 
638 patients with HF who participated an inpatient rehabilitation program, 86 patients underwent 21 
CPX, and 49 patients met the inclusion criteria. A symptom-limited exercise test with cycle ergometer 22 
and a 6MWT were conducted within a time interval of 24-48 h in the discharge period (Kervio et al., 23 
2004). The patients were divided into two groups using a 6MWD of 300 m as the cut-off (Metra et al., 24 
2007; Writing Committee Members et al., 2013); the first group walked 300 m or more (HF-M, n = 34, 25 
21 women), and the second group walked less than 300 m (HF-L, n = 15, five women) (Table 1). 26 
Exclusion criteria were acute coronary syndrome or myocardial infarction, uncontrolled arrhythmia, 27 
severe aortic stenosis, acute phase of pulmonary embolism, and acute myocarditis. Patients were also 28 
㸱 
 
excluded if they had significant respiratory disease and if their activity was limited by health 1 
conditions other than fatigue and exertional dyspnea (such as neurologic impairments, orthopedic 2 
impairments) for locomotor impairments. Patients who were not able to walk for six-minutes 3 
continuously without rests, and who showed significant anxiety or had difficulty in understanding this 4 
study were also excluded (Kervio et al., 2004; Lipkin, Scriven, Crake, and Poole-Wilson, 1986) 5 
(Figure 1).  6 
All patients participated in an inpatient rehabilitation program and were clinically stable 7 
(Mebazaa et al., 2015) at the time of this study. The program was composed of several phases. The 8 
first phase aimed for prevention the deleterious effects of bed rest, to improve functionality, and 9 
prepare a safer return to daily life activities. The following phases were positioning, range of motion 10 
exercises during bed rest, sitting mild resistance, flexibility exercises, standing, and ambulation in 11 
room to a ward corridor (Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008). Thereafter, 12 
cycling or treadmill walking with warm-up and cool-down exercises was conducted at physical 13 
therapy department. Cycling or treadmill walking exercises was conducted for 15 to 20-min and was 14 
adjusted according to rating of perceived exertion with Borg scale 11-13, and  vital signs (such as 15 
blood pressure, the heart rate) (Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008; Piepoli 16 
et al., 2011). 17 
 Approval by the institutional review board was obtained before the study was initiated 18 
(approval number 2014020), and all patients provided their written, informed consent to participate in 19 
the study. 20 
 21 
Protocol 22 
Each participant performed a cycle ergometer, symptom-limited exercise test and a 6MWT in 23 
the discharge period (Kervio et al., 2004), and each test was conducted randomly. This narrow time 24 
frame aimed to limit the potential effects of changes in patients’ clinical status. Both exercise tests 25 
were conducted more than 2 hours after a meal and any oral drug ingestion. None of the participants 26 
were notified of any results prior the completion of the whole protocol. Handgrip strength (HS) was 27 
also measured by a handgrip dynamometer T.K.K.5401 GRIP-D (Takei Scientific Instruments Co., 28 
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Ltd, Niigata, Japan). The highest result of three attempts each on both hands was recorded. 1 
 2 
Six-minute walk test 3 
The FitMate Pro (FIT-2200, COSMED, Rome, Italy) was used for measurement of 4 
cardiorespiratory parameters. The instrument is a portable metabolic measurement system for 5 
measuring V
㸬
O2 in both clinical and athletic exercise testing. It uses a turbine flowmeter to measure 6 
ventilation and a galvanic fuel cell oxygen sensor for analyzing the fraction of expired oxygen. The 7 
metabolic system is reliable and valid for measurement of V
㸬
O2 in adults (Nieman et al., 2007). 8 
Sampling data were averaged over 15-second intervals and recorded every 30 seconds. The system 9 
was carefully calibrated before each test. V
㸬
O2 (ml/kg/min), minute ventilation (V
㸬
E, l/min), and 10 
breathing frequency (f, breaths/min) during the 6MWT were recorded using The FitMate Pro. Tidal 11 
volume (VT, liter) was obtained by dividing V
㸬
E by f. The heart rate (HR) was also recorded via 12 
electrocardiographic telemetry (DYNASCOPE; Fukuda Denshi Co., Ltd., Tokyo, Japan) and 13 
synchronized with other cardiorespiratory parameters. 14 
The 6MWT was performed according to a standardized protocol (ATS Committee on 15 
Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002; Guyatt et al., 1985). 16 
Participants sat on a chair for 3 min before the walking test and then walked along a 30-m, flat, 17 
obstacle-free corridor at a self-selected speed. The patients were instructed to walk as far as possible, 18 
turning 180° every 30 m. After the walking test, patients again sat on a chair for 3 min. Baseline V
㸬
O2 19 
was calculated by averaging the measurements made for 2 min before the beginning of exercise 20 
(Nanas et al., 2001). Separately from the gas analysis test during the 6MWT, the total distance walked 21 
during six minutes was measured in meters (m) as the 6MWD by the same protocol as the gas 22 
analysis test. 23 
 24 
Cycle ergometer test  25 
All patients underwent a symptom-limited, graded exercise test on a cycle ergometer 26 
according to the modified Ramp protocol with a cycle ergometer (Well Bike BE-250, Fukuda Denshi 27 
Co., Ltd., Tokyo, Japan), a CPX monitoring system (STRESS TEST SYSTEM ML-9000, Fukuda 28 
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Denshi Co., Ltd.), and a gas analysis system Cpex-1 (Inter Reha, Tokyo, Japan) by a breath-by-breath 1 
method. After 3 min of unloaded pedaling, the initial workload was 10 Watts, and it was increased 2 
with a 10 Watts/min ramp until patients reached exhaustion. Patients were encouraged to cycle up to 3 
their true maximal effort during the test, defined by leg fatigue and/or dyspnea. Fatigue and dyspnea 4 
during cycle ergometer test were quantified by rating of perceived exertion with Borg scale. V
㸬
O2peak, 5 
anaerobic threshold (AT), the relationship between minute ventilation and carbon dioxide production 6 
(V
㸬
E/V
㸬
CO2 slope), and peak O2 pulse were recorded. V
㸬
O2peak was defined as the average of values 7 
obtained during the last 30 seconds of exercise. AT was determined using the V-slope method 8 
(Pereira et al., 2010), and the AT was counterchecked using the nadir of ventilatory equivalents in 9 
cases of uncertainty (Deboeck et al., 2014). 10 
 11 
Statistical analysis  12 
The data are presented as means ± SD. Data analyses were conducted using JMP® 13 (SAS 13 
Institute Inc., Cary, NC, USA). Between-group comparisons were made with the unpaired t-test, 14 
Mann-Whitney U test, and χ2 test as appropriate for baseline characteristics. Effect sizes were 15 
calculated using G*Power 3.1 (Faul, Erdfelder, Lang, and Buchner, 2007). The time course of 16 
cardiorespiratory values including V
㸬
O2, V
㸬
E, and HR during the 6MWT was analyzed in each group 17 
using one-way repeated measures ANOVA, followed, when significant, by Tukey’s method. Before 18 
the ANOVA, each variable of the physiologic profile throughout the 6MWT was confirmed to follow 19 
a normal distribution by the Shapiro-Wilk test and Mauchly’s sphericity test. The definition of steady 20 
state was the first point in time after which there was no further statistical significant difference 21 
during the 6MWT in each value of V
㸬
O2, V
㸬
E, and HR (Kervio et al., 2004). The beginning of recovery 22 
corresponded to be the point at which no further changes compared to the resting baseline before the 23 
6MWT occurred (Witte et al., 2005). The resting baseline was adopted the mean value of 3 min 24 
before 6MWT started in each value of V
㸬
O2, V
㸬
E, and HR. Pearson’s correlation coefficient was used 25 
to assess the relationships between 6MWD and values that were recorded by CPX, and to determine 26 
the correlation between VT and f during the 6MWT in both groups. Statistical significance was 27 
accepted at P < 0.05.  28 
㸴 
 
 1 
RESULTS 2 
 The baseline characteristics are shown in Table 1. There were no differences between the 3 
groups in terms of age, proportions of males and females, BMI, LVEF, and beta-blocker use. Patients 4 
in the HF-L group walked shorter 6MWD and had lower HS than the HF-M group. On CPX, 5 
compared with the HF-L group,  V
㸬
O2peak (15.79 ± 3.90 vs. 12.08 ± 3.37 ml/kg/min ; P < 0.01), AT 6 
(12.06 ± 2.59 vs. 9.50 ± 2.88 ml/kg/min ; P < 0.01), and peak O2 pulse (8.68 ± 2.24 vs. 7.06 ± 1.58 7 
ml/beat ; P < 0.01) were significantly higher, while V
㸬
E/V
㸬
CO2 slope (27.44 ± 5.71 vs. 34.53 ± 6.51 ; P 8 
< 0.001) was significantly lower in the HF-M group (Table 1). 9 
Significant positive correlations were observed between the 6MWD and V
㸬
O2peak (r = 0.62, P 10 
< 0.001), AT (r = 0.55, P < 0.001), and peak O2 pulse (r = 0.41, P < 0.01). The 6MWD and V
㸬
E/V
㸬
CO2 11 
slope showed a significant negative correlation (r = 㸫0.57, P < 0.001) (Figure 2). 12 
Figure 3 shows the cardiorespiratory kinetics before, during, and after the 6MWT in both 13 
groups. In the HF-M group, V
㸬
O2 was stabilized from 3 min during the 6MWT and recovered for 3 14 
min after the 6MWT ended. V
㸬
E was stabilized from 3 min and recovered for 3 min after the 6MWT 15 
ended. HR stabilized from 3 min and recovered for 1 min 30 s. In the HF-L group, V
㸬
O2 was stabilized 16 
from 4 min during the 6MWT and did not recover within 3 min after the 6MWT ended. V
㸬
E was 17 
stabilized from 4 min and did not recover within 3 min after the 6MWT ended. HR stabilized from 3 18 
min and recovered for 1 min 30 s (Figure 3).  19 
With regard to the breathing pattern of each group, in the HF-M group, VE rose from 8.26 ± 20 
2.01 l/min at rest to 17.95 ± 5.00 ml/min at the sixth minute of the 6MWT. The increase in VE was 21 
due to both an increase in VT (rest VT 0.48 ± 0.12 l vs. the sixth minute VT of the 6MWT 0.79 ± 0.22 l, 22 
P < 0.001) and an increase in f (rest f 17.68 ± 4.07 vs. the sixth minute f of the 6MWT 23.10 ± 4.28, P 23 
< 0.001). In the HF-L group, VE rose from 7.44 ± 1.81 l/min at rest to 17.62 ± 4.46 ml/min at the 24 
sixth minute of the 6MWT. The increase in VE was also due to increases in VT (rest VT 0.43 ± 0.17 l 25 
vs. the sixth minute VT of the 6MWT 0.68 ± 0.18 l, P < 0.001) and f (rest f 18.25 ± 5.35 vs. the sixth 26 
minute f of the 6MWT 26.79 ± 6.41, P < 0.001). Additionally, as shown in Figure 4, comparing the 27 
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VT and f relationship during the 6MWT between the two groups, the relationship in the HF-L group 1 
shifted gradually to the upper left due to increasing f throughout the 6MWT compared to the HF-M 2 
group. 3 
 4 
DISCUSSION 5 
 The results of the present study suggested that the kinetics of cardiorespiratory parameters 6 
during and after the 6MWD in patients with HF have several differences according to the 6MWD. 7 
Furthermore, varying breathing patterns were seen during the 6MWT.  8 
 In this study, steady state of V
㸬
O2 during the 6MWT was from 3 min in the HF-M group and 4 9 
min in the HF-L group. Additionally, the HF-L group had lower V
㸬
O2peak , AT, and HS compared to 10 
the HF-M group. Kervio et al. (2004) reported that the time to steady state V
㸬
O2 during the 6MWT was 11 
longer in patients with HF (3-5 min) than in healthy participants (2 min 30 s). The delayed O2 kinetics 12 
in patients with HF were linked to a decrease in O2 availability to poorly perfused segments of 13 
exercising muscles as a result of an insufficient increase in cardiac output (Guazzi et al., 2016; Witte 14 
et al., 2005) and slower adaptation of cardiac function (Deboeck, Van Muylem, Vachiéry, and Naeije, 15 
2014). This slower V
㸬
O2 response may not only include abnormalities in cardiac function, but also in 16 
peripheral mechanisms. The abnormalities related to limitations in O2 delivery in patients with HF 17 
(Fleg et al., 2015; Okita et al., 1998; Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008; 18 
Witte et al., 2005) include reduced nutritive blood flow to the active skeletal muscles, decreased 19 
capillary density, diminished oxidative capacity, abnormal peripheral circulation affected by 20 
neurohumoral mechanisms (Fleg et al., 2015; Francis, 1985;  Papathanasiou, Tsamis, Georgiadou, and 21 
Adamopoulos, 2008; Solal, Chabernaud, and Gourgon, 1990), and the worsening local acidosis (Witte 22 
et al., 2005). The decreased O2 availability in the exercising muscles leads to slower V
㸬
O2 kinetics, 23 
because pulmonary V
㸬
O2 kinetics reflect muscular V
㸬
O2 during the onset of constant load exercise 24 
(Koike et al., 1995). Moreover, impaired muscle metabolism associated with early metabolic 25 
limitation in patients with HF, and they are dependent on the degree of exertion performed, which is 26 
related to peak functional capacity that reflects time of onset for O2 (Okita et al., 1998; Witte et al., 27 
2005). Additionally, reduced ventilatory efficiency may also contribute to delayed oxygen kinetics 28 
㸶 
 
(Brunner-La Rocca et al., 1999). Therefore, our results may be related with differences of exercise 1 
capacity including skeletal muscle functions.  2 
In the present study, the recoveries of both V
㸬
O2 and V
㸬
E after the 6MWT ended were slower 3 
in the HF-L group. It is well known that O2 deficit and O2 debt have relationships with constant load 4 
exercise in healthy participants (Whipp, Seard, and Wasserman, 1970), and patients with HF have a 5 
slow increase of V
㸬
O2 following the onset of exercise, which is associated with prolonged recovery 6 
time in prior study using CPX (Fleg et al., 2005; Sietsema et al., 1994). O2 debt, namely, oxygen 7 
consumption during recovery above the control level, equaled O2 deficit when exercise lasted 4 min 8 
and longer (Whipp, Seard, and Wasserman, 1970). Time of recovery O2 kinetics depends on the 9 
workload and the proportion of functional capacity of the individual (Koike et al., 1995; Nanas et al., 10 
2001; Witte et al., 2005). It is common knowledge that exercise training can improve exercise 11 
capacity and skeletal O2 delivery due to multiple mechanisms (Fleg et al., 2015; Inamdar, and 12 
Inamdar, 2016; Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008; Piña et al., 2003; 13 
Roditis et al., 2007; Writing Committee Members et al., 2013).  14 
As shown in Figure 3, HR recovered earlier than V
㸬
O2 and V
㸬
E in both groups. Moreover, in 15 
the present study, 45 patients (91.8%) were receiving β-blockers, and there was no difference between 16 
the groups in terms of their usage. β-blockers have been recommended for several years in 17 
international guidelines as a standard therapy in HF (McMurray et al., 2012). β-blockers are the 18 
primary pharmacological option available to lower HR. There is a linear correlation between V
㸬
O2 and 19 
HR. On the other hand, in patients with HF, this correlation is only certain for those who use a full 20 
dose of β-blockers and have a resting HR of 50 to 60 beats per minute (Carvalho, Guimaraes, and 21 
Bocchi, 2008). Monitoring exercise intensity based on the HR alone should be avoided, especially in 22 
patients who are taking β-blockers, since patients with HF have a poor chronotropic response to 23 
exercise (Brubaker, and Kitzman, 2013; Piña et al., 2003). For these reasons, the HR might not 24 
adequately reflect the intensity of exercise, which includes the 6MWT, compared with other 25 
cardiopulmonary parameters. 26 
Comparing the HF-L group to the HF-M group, the kinetics of V
㸬
E during the 6MWT showed 27 
slower increases and patients in the HF-L group have lower V
㸬
E  (Figure3) Furthermore, their 28 
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breathing pattern seemed to be composed of lower VT and higher f throughout the 6MWT comparing 1 
the HF-M. Patients with HF have lower functional capacity and V
㸬
E compared with age-matched 2 
healthy controls assessed using CPX (Clark, Chua, and Coats, 1995; Deboeck, Van Muylem, 3 
Vachiéry, and Naeije, 2014; Zavin et al., 2013). The V
㸬
E values increased throughout the 6MWT in 4 
patients with HF, and this drift could be due to their higher intensity maintained during the test 5 
(Kervio et al., 2004). Patients with HF have an altered ventilatory response to exercise, primarily 6 
rapid shallow respiration (Dimopoulou, Tsintzas, Alivizatos, and Tzelepis, 2001; McConnell, 2004). 7 
Specific breathing patterns in patients with HF are associated with greater impairment in functional 8 
capacity, and are less efficient because it contributes to relatively lower VT, higher f, and increased 9 
dead space ventilation (Dimopoulou, Tsintzas, Alivizatos, and Tzelepis, 2001; McConnell, 2004). 10 
Pulmonary dysfunction in patients with HF is composed of ventilation-perfusion mismatching, 11 
decreased lung compliance, restriction, airway obstruction, and decreased respiratory and skeletal 12 
muscle strength (Dall'Ago et al., 2006; McConnell, 2004). In addition to these factors, which 13 
contribute to the ventilatory response to exercise in patients with HF, increased afferent neural activity 14 
from the large locomotor muscles is related to metabolites generated during exercise (Olson, Joyner, 15 
and Johnson, 2010). Consequently, this results in an inefficient breathing pattern and increased work 16 
of breathing (McConnell, 2004). Typically, the most efficient pattern is adopted due to adaptation to 17 
the disease by the cardiorespiratory control systems (Davies et al., 1992). Possible mechanisms in 18 
current study may include a significantly higher V
㸬
E/V
㸬
CO2 slope in the HF-L group (Table 1). 19 
V
㸬
E/V
㸬
CO2 slope is a variable reflecting ventilatory efficiency in patients with HF and is related to an 20 
excessive ventilatory response during exercise with skeletal muscle metabolic production (Arena et al., 21 
2004; Guazzi et al., 2016; Olson, Joyner, and Johnson, 2010). A high V
㸬
E/V
㸬
CO2 slope is an important 22 
prognostic marker in patients with HF, and the degree of slope elevation increases with disease 23 
severity (Arena et al., 2004; Guazzi et al., 2016; Metra et al., 2007), which is associated with 24 
increasing dead space (Clark , Chua, and Coats, 1995).  25 
The 6MWT is an useful measure of functional capacity and is a powerful indicator for HF 26 
patients due to correlations with V
㸬
O2peak and V
㸬
O2max of CPX (Guyatt et al., 1985; Metra et al., 2007; 27 
Opasich et al., 2001; Papathanasiou, Tsamis, Georgiadou, and Adamopoulos, 2008; Piepoli et al., 28 
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2011; Writing Committee Members et al., 2013), whereas the 6MWT does not accurately predict 1 
functional capacity in older HF patients (Maldonado-Martín et al., 2006). Age, sex, and body mass 2 
index must be considered when the 6MWT is used for the assessment of HF patients because these 3 
factors have an important influence on 6MWT performance (Metra et al., 2007). On the other hand, 4 
previous studies have shown that V
㸬
O2 peak and AT are still the best indicators of functional capacity 5 
also in HF patients (Guazzi et al., 2016; Metra et al., 2007; Pereira et al., 2010). The current study 6 
showed that the 6MWD was correlated with V
㸬
O2peak and AT measured by CPX. Therefore, it is 7 
conceivable that 6MWD in the present study is a parameter of functional capacity.  8 
In the interpretation of the present study results, some limitations should be considered. The 9 
sample size was small, and there was no healthy control group. Additionally, there is a difference of 10 
the sample sizes between two groups, and the timing of the protocol from onset of HF was not 11 
stipulated. The assessor of the 6MWT with portable metabolic measurement system was the same 12 
physical therapist and it could be potential of assessor’s bias. In our current study, we investigated the 13 
relationship between 6MWD and values that were recorded by CPX. However, the 6MWT is not able 14 
to supersede CPX as the same role of measurement. Moreover, the relationship between VT and f 15 
during the 6MWT in both groups were investigated with correlations and it might not clarify causal 16 
relationship. Other limitations of this study are the effects of type of HF (HFrEF, HFmrEF, and 17 
HFpEF) (Ponikowski et al., 2016) and the etiology of HF (Antunes-Correa et al., 2017). Further 18 
research that takes into account the pathophysiological characteristics is needed. 19 
 20 
CONCLUSION 21 
The cardiorespiratory responses during and after the 6MWT differ according to the 6MWD. 22 
In lower exercise capacity patients with HF have slower V
㸬
O2 and VE kinetics, and their breathing 23 
pattern during the 6MWT seems to consist of a higher breathing frequency and a lower VT. 24 
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 9 
Footnotes 10 
1. New York Heart Association Functional Classification (The Criteria Committee of the New York 11 
Heart Association, 1994) 12 
Class I. No limitation of physical activity. 13 
Class II. Slight limitation of physical activity. Ordinary physical activity results in symptoms 14 
including fatigue, palpitation, dyspnea, or anginal pain. 15 
Class III. Marked limitation of physical activity. Less than ordinary activity causes symptoms. 16 
Class IV. Symptoms even at rest. 17 
㸯 
 
Table 1. Baseline characteristics and exercise data of each group 
Variables HF-M HF-L 95% CI of 
difference 
P-value Effect 
size 
n 34 15    
Age * (years) 68.86 ± 11.24 72.27 ± 12.42 - 3.78 to 10.60 0.17 0.29 
Sex † (male/female) 13/21 10/5 - 0.53 to 0.01 0.06  0.44 
BMI * (kg/m2) 22.28 ± 3.93 22.80 ± 4.12 - 2.02 to 3.06 0.28 0.15 
LVEF ‡ (%) 37 (22.7-57.5) 34 (30-53) - 10.97 to 12.83 0.76 0.20 
NYHA class1 † 
 II/ III (n) 
 
32/ 2 
 
8/ 7 
  
< 0.01 
 
0.49 
Etiology of HF †  (n) 
Ischemic Cardiomyopathy  
Cardiomyopathy 
Valvular disease 
Arrhythmia 
 
1 
19 
10 
4 
 
1 
10 
4 
0 
 0.50 0.22 
 
 
 
Current prescription † (n) 
Beata blockers 
ACE inhibitor 
ARB 
Diuretics 
Aldosterone antagonists 
 
31 
17 
23 
31 
22 
 
14 
7 
8 
14 
9 
 
 
 
 
 
 
 
0.27 
0.68 
0.33 
0.79 
0.75 
 
0.06 
0.05 
0.14 
0.04 
0.05 
Hospitalization days*(days) 25.02 ± 12.44 28.60 ± 10.17 - 6.37 to 13.51 0.85 0.31 
Duration of the inpatient 
rehabilitation program* 
(days) 
18.94 ± 10.06 22.80 ± 10.36 - 4.46 to 12.18 0.54 0.38 
6MWD (m) * 412.20 ± 10.03 228.33 ± 15.10 -220.35 to – 
147.39 
< 0.001 14.43 
㸰 
 
Handgrip strength* (kg) 27.15 ± 6.44 16.80 ± 4.40 6.65 to 14.04 < 0.001 1.87 
CPX 
V
㸬
O2 peak* (ml/kg/min) 
AT* (ml/kg/min) 
V
㸬
E/V
㸬
CO2 slope* 
peak O2 pulse* (ml/beat) 
 
15.79 ± 3.90 
12.06 ± 2.59 
27.44 ± 5.71 
8.68 ± 2.24 
 
12.08 ± 3.37 
9.50 ± 2.88 
34.53 ± 6.51 
7.06 ± 1.58 
 
1.36 to 6.04 
0.88 to 4.23 
3.37 to 10.80 
0.32 to 2.90 
 
< 0.01 
< 0.01 
< 0.001 
< 0.01 
 
0.92 
0.93 
1.16 
0.70 
 
*Data presented as mean ± standard deviation and the unpaired t-test was used. †Data presented as 
number and chi̻square test was used. ‡Data presented as median (interquartile range) and Mann̻
Whitney U test was used. 
n, number; BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart 
Association; HF, heart failure; ACE, angiotensin-converting enzyme; ARB, Angiotensin II Receptor 
Blocker; 6MWD, the 6-minute walk distance; CPX, cardiopulmonary exercise testing; V
㸬
O2peak, peak 
oxygen uptake; AT, anaerobic threshold; V
㸬
E/V
㸬
CO2 slope, the minute ventilation - carbon dioxide 
production relationship; peak O2 pulse, peak oxygen pulse.  
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Figure captions 
 
Figure 1: A flow chart of patients included in this study 
Figure 2: Correlations of the 6-minute walk distance (6MWD) with peak oxygen uptake (V
㸬
O2 peak), 
anaerobic threshold (AT), the relationship between minute ventilation and carbon dioxide production 
(V
㸬
E/V
㸬
CO2 slope), and peak O2 pulse in a cardiopulmonary exercise test 
Figure 3: Kinetics of the cardiorespiratory parameters before, during, and after the 6MWT in patients 
with heart failure who walked 300 m or more (HF-M), and patients with heart failure who walked less 
than 300 m (HF-L) 
Figure 4: The correlation between tidal volume (VT) and breathing frequency (f) during the 6MWT in 
patients with heart failure who walked 300 m or more (HF-M), and patients with heart failure who 
walked less than 300 m (HF-L) 
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Figure 1. A flow chart of patients included in this study. 
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Figure 2. Correlations of the 6-minute walk distance (6MWD) with peak oxygen uptake (V
㸬
O2 peak), 
anaerobic threshold (AT), the relationship between minute ventilation and carbon dioxide production 
(V
㸬
E/V
㸬
CO2 slope), and peak O2 pulse in a cardiopulmonary exercise test. Pearson’s correlation 
coefficient was used to determine the correlation among the variables. 
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Figure 3. Kinetics of the cardiorespiratory parameters before, during, and after the 6MWT (V
㸬
O2, 
oxygen uptake; V
㸬
E, minute ventilation; HR, heart rate) in patients with heart failure who walked 300 
㸴 
 
m or more (HF-M, ی), and patients with heart failure who walked less than 300 m (HF-L, ●). The 
time between the broken lines indicates the 6MWT. The open triangle symbols indicate the 
cardiorespiratory parameters steady state during the 6MWT and recovery point after the 6MWT. The 
time course of cardiorespiratory values including V
㸬
O2, V
㸬
E, and HR during the 6MWT was analyzed 
in each group using one-way repeated measures ANOVA, followed, when significant, by Tukey’s 
method. The definition of steady state was the first point in time after which there was no further 
statistical significant difference during the 6MWT in each value of V
㸬
O2, V
㸬
E, and HR. The beginning 
of recovery corresponded to be the point at which no further changes compared to the resting baseline 
before the 6MWT occurred (Witte et al, 2005). The resting baseline was adopted the mean value of 3 
min before 6MWT started in each value of V
㸬
O2, V
㸬
E, and HR. 
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Figure 4.  The correlation between tidal volume (VT) and breathing frequency (f) during the 6MWT 
in patients with heart failure who walked 300 m or more (HF-M, ی) and patients with heart failure 
who walked less than 300 m (HF-L, ●). Pearson’s correlation coefficient was used to determine the 
㸷 
 
correlation between VT and f every 30 seconds during the 6MWT. 
 
 
